[Case Report: MPO-ANCA Associated Vasculitis After Pfizer-BioNTech COVID-19 mRNA Vaccination]

G Ital Nefrol. 2023 Aug 31;40(4):2023-vol4.
[Article in Italian]

Abstract

We report a case of MPO-anti-neutrophil cytoplasmic antibody ANCA-associated vasculitis, with pulmonary-renal syndrome, after the mRNA booster third dose vaccine Pfizer BioNTech against COVID-19 in 71-year-old Caucasian man with no specific past medical history. A kidney biopsy diagnosed ANCA-associated pauci-immune crescentic glomerulonephritis. Renal function and constitutional symptoms have been partially improved with treatment with dialysis, intravenous rituximab and steroid pulse therapy. No disease following either infection or vaccination with fourth dose against COVID-19.

Keywords: ANCA vasculitis; SARS-CoV-2; booster dose; cytokine storm; mRNA vaccine.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / diagnosis
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
  • Antibodies, Antineutrophil Cytoplasmic / therapeutic use
  • COVID-19*
  • Glomerulonephritis*
  • Humans
  • Lung Diseases*
  • Male

Substances

  • Antibodies, Antineutrophil Cytoplasmic